HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Th... ( Expanded Range of HER1 HER2 and HER3 ...)

HOME >> BIOLOGY >> TECHNOLOGY

HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics

Date:5/1/2008

Expanded Range of HER1, HER2 and HER3 Assays to Provide Unique Insights and

Facilitate Development of Personalized Cancer Therapies

SOUTH SAN FRANCISCO, May 1 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that the company's HER1 and HER3 Quantitative Protein Assays are now available for clinical development use. Built on Monogram's VeraTag(TM) platform, the HER1 and HER3 assays provide unique, quantitative measurements of protein expression and activity in formalin fixed paraffin embedded (FFPE) tumor samples. These assays supplement HERmark(TM), Monogram's HER2 and HER2:HER2 Homodimer Breast Cancer Assay, and expands the potential clinical reach of Monogram's VeraTag assays to lung, colorectal and other cancers.

"We are excited to make the HER1 and HER3 assays available for clinical development use," said William Young, president and CEO of Monogram Biosciences. "Our first VeraTag product, HERmark, is already available for use in clinical development programs through our CLIA-approved laboratory and provides quantitative and accurate measurements of the expression of HER2 and HER2:HER2 homodimers. The addition of the HER1 and HER3 assays expands the reach of our VeraTag technology and we look forward to forging collaborations with biopharmaceutical companies to advance the use of our diagnostics and enable the development of new treatment options for those living with cancer."

"Oncologists have long known about the role that HER2 plays in breast cancer and, although far from perfect, have had some tools available to measure it," said Michael Bates, M.D., Monogram vice president of clinical research. "Accurate, quantitative measurements for EGFR (HER1) and HER3 have never
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Genetic Engineering & Biotechnology News reports on growing use of cell-based assays
2. Genetic Engineering & Biotechnology News Reports on Growing Use of Cell-Based Assays
3. Cellix Ltd. Launches VenaEC Biochip for Flow-based Cell-adhesion Assays
4. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
5. UltraTape Announces Sample Kits Available for Purchase Through Website
6. Baxters V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals
7. ALCiS(R) Daily Relief Now Available at Walgreens
8. pH Balanced RepHresh Vaginal Gel(R) now Available to Women in Canada Attacking Tough, Embarrassing Feminine Issues
9. Marteks lifesDHA(TM) Now Available in Protein-free Powder
10. Canadas Best-Selling Soymilk Now Available with Marteks lifesDHA
11. Vaccinogens New Anti-Cancer Vaccine Commercially Available in Europe This Year

Post Your Comments:

HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Th...( Expanded Range of HER1 HER2 and HER3 ...)